SEC crypto ETF approvals

The question "when will the SEC approve X" dominated crypto coverage for a decade. It is now largely the wrong question, because the mechanism that made it interesting has been replaced. This page explains what changed, and why it matters more than any individual approval.

How it used to work

For a new exchange-traded product of a novel type to list in the US, the exchange had to file a proposed rule change with the SEC — a 19b-4 — and wait through a statutory review period that could run to 240 days. Separately, the issuer had to get its registration statement, the S-1, declared effective. Both had to land.

For spot bitcoin, the 19b-4 was the wall. The SEC rejected application after application from 2013 onwards, consistently citing the same concern: the underlying spot market was susceptible to fraud and manipulation, and there was no surveillance-sharing agreement with a regulated market of significant size.

The workaround was futures. Because CME bitcoin futures trade on a CFTC-regulated venue, the SEC was willing to approve funds holding them, and the first US bitcoin futures ETF listed in October 2021. The result was three years in which American investors could buy a fund built on a regulated derivative of an asset the regulator would not let them hold through a fund.

The 2024 breakthrough

The position was resolved against the SEC rather than by it. Grayscale challenged the rejection of its conversion application in court and won, on the reasoning that treating spot and futures products differently, when both derived their value from the same underlying market, was arbitrary.

The SEC approved spot bitcoin exchange-traded products on 10 January 2024. Eleven funds listed the next day.

Generic listing standards

This is the change that actually reshaped the market, and it received a fraction of the coverage that the 2024 approval did.

On 18 September 2025 the SEC adopted generic listing standards for commodity-based trust shares. In plain terms: exchanges can now list a product that meets a set of standing criteria without filing a bespoke rule change for it. The per-product negotiation with the regulator is gone for anything that qualifies.

Reported approval timelines fell from roughly nine months to about 75 days. The SEC asked issuers with pending 19b-4 filings for solana, XRP, dogecoin, cardano and litecoin to withdraw them — because those filings had become unnecessary, not because the applications were being refused.

The consequence is visible in the launch pattern. Solana funds arrived in late October 2025, XRP funds in November, and what had been a trickle of individually negotiated approvals became a market where products launch when a sponsor decides one is commercially worth running.

What the filings actually are

Three documents come up constantly in coverage of this market and they do different jobs.

• 19b-4. A proposed rule change filed by an exchange, asking permission to list a type of product. This was the bottleneck. Largely superseded by generic listing standards for qualifying products.
• S-1. The issuer's registration statement — the disclosure document describing the trust, its custodian, its fees and its risks. It has to be declared effective before shares can be sold. This is now the main gate.
• 10-K and 10-Q. Annual and quarterly reports filed once the product is running. These are where you find holdings, expenses and the auditor's view, and they are considerably more informative than any factsheet.

How to track a pending product properly

If you want to follow this yourself rather than through headlines, the route is short.

Go to SEC EDGAR. It is the primary source, it is free, and everything else is downstream of it. Search by the sponsor's name and read the S-1 or its amendments. The absence of a filing is more informative than most articles claiming an approval is imminent.

Read the risk factors section. It is the least-read and most useful part of any S-1. It is where the sponsor is legally obliged to tell you what could go wrong, and it is consistently blunter than anything in the marketing.

Ignore prediction-market odds presented as analysis. A number from a betting market is a price, not a forecast produced by anyone with information. A great deal of crypto ETF coverage consists of reprinting these with a confident headline.

Three things people misread

"SEC approval" is not endorsement. It means the product met listing and disclosure requirements. The SEC does not express a view on whether an asset is a good investment, and it has said so repeatedly.

An approval is not a price event you can trade. By the time an approval is announced it has usually been anticipated for months. The idea that approvals mechanically move prices in a predictable direction is not supported by how the 2024 launch actually played out.

A US approval does not create UK access. This is the one that costs British readers the most, and it is the reason this site exists.

Why UK rules are separate

The SEC and the FCA are unrelated regulators with separate statutory mandates, and there is no mechanism by which an American approval creates a British permission.

The UK position is set entirely by the FCA. It banned crypto derivatives and crypto ETNs for retail consumers in January 2021. It lifted the ETN half on 8 October 2025 for products admitted to trading on a UK recognised investment exchange, and explicitly kept the derivatives restriction — and with it the barrier to crypto ETFs — in place.

So the sequence that matters to a UK reader is: the SEC decides what exists in America, the FCA decides what you can buy, and HMRC decides what wrapper you can hold it in. The third of those changed on 6 April 2026 and is covered on our ISA page. All three are independent of each other.